I 
118TH CONGRESS 
1ST SESSION H. R. 6749 
To require the Director of the National Institutes of Health to evaluate 
the results and status of completed and ongoing research related to 
menopause, perimenopause, or mid-life women’s health, to conduct and 
support additional such research, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
DECEMBER 13, 2023 
Ms. CLARKE of New York (for herself, Mrs. LESKO, Ms. BLUNT ROCHESTER, 
Ms. HOULAHAN, Mr. RYAN, Ms. WILD, Ms. LEE of California, Mrs. 
CAMMACK, Ms. VELA´ZQUEZ, Mr. POSEY, Ms. SEWELL, Mr. GRIJALVA, 
Ms. TLAIB, Ms. WILLIAMS of Georgia, Mrs. RAMIREZ, Mr. TONKO, Ms. 
NORTON, Mr. NADLER, Ms. MOORE of Wisconsin, Mr. DAVIS of North 
Carolina, Ms. PORTER, Mr. GREEN of Texas, Ms. CROCKETT, Mr. 
ALLRED, Mrs. CHERFILUS-MCCORMICK, Ms. KELLY of Illinois, Mr. 
JACKSON
of Illinois, Mr. LAWLER, Mrs. WATSON
COLEMAN, Ms. 
BARRAGA´N, Ms. CARAVEO, Mr. GARCI´A of Illinois, Mr. TRONE, Mr. 
VARGAS, Mrs. BEATTY, Mrs. FLETCHER, Mr. FITZPATRICK, Ms. 
KUSTER, Ms. ADAMS, Ms. PINGREE, and Mr. TAKANO) introduced the 
following bill; which was referred to the Committee on Energy and Com-
merce 
A BILL 
To require the Director of the National Institutes of Health 
to evaluate the results and status of completed and ongo-
ing research related to menopause, perimenopause, or 
mid-life women’s health, to conduct and support addi-
tional such research, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
VerDate Sep 11 2014 
23:38 Dec 29, 2023
Jkt 049200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H6749.IH
H6749
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Menopause Research 
and Equity Act of 2023’’. 
SEC. 2. EVALUATION OF COMPLETED AND ONGOING RE-
SEARCH 
RELATED 
TO 
MENOPAUSE, 
PERIMENOPAUSE, 
OR 
MID-LIFE 
WOMEN’S 
HEALTH. 
(a) IN GENERAL.—The Director of the National In-
stitutes of Health shall— 
(1) conduct an evaluation of— 
(A) the results of research related to meno-
pause, perimenopause, or mid-life women’s 
health that is complete; 
(B) the status of such research that is on-
going; and 
(C) any gaps in knowledge and research 
on— 
(i) treatments for menopause-related 
symptoms; and 
(ii) the safety and effectiveness of 
treatments for menopause-related symp-
toms; and 
(2) as part of such evaluation, identify the total 
amount of funding allocated by the National Insti-
tutes of Health for the conduct or support of re-
search related to menopause, perimenopause, or 
VerDate Sep 11 2014 
23:38 Dec 29, 2023
Jkt 049200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H6749.IH
H6749
mid-life women’s health over the preceding 5 fiscal 
years. 
(b) REPORT; STRATEGIC PLAN.—Not later than 180 
days after the date of enactment of this Act, the Director 
of the National Institutes of Health shall submit to the 
Congress— 
(1) a plan to perform the evaluation under sub-
section (a); and 
(2) a plan to develop a strategy, based on such 
evaluation, that will— 
(A) be designed and implemented by the 
Director in cooperation with a multidisciplinary 
group of health professionals including gyne-
cologists, oncologists, endocrinologists, cardiolo-
gists, and neuroscientists; 
(B) include strategies to resolve the gaps 
in knowledge and research identified in the re-
port; and 
(C) identify topics in need of further re-
search relating to potential treatments for 
menopause-related symptoms. 
SEC. 3. ADDITIONAL RESEARCH RELATED TO MENOPAUSE, 
PERIMENOPAUSE, 
OR 
MID-LIFE 
WOMEN’S 
HEALTH. 
(a) ADDITIONAL RESEARCH.— 
VerDate Sep 11 2014 
23:38 Dec 29, 2023
Jkt 049200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H6749.IH
H6749
(1) IN GENERAL.—The Secretary of Health and 
Human Services, acting through the Director of the 
National Institutes of Health, shall conduct or sup-
port research related to menopause, perimenopause, 
or mid-life women’s health. 
(2) REQUIRED
ELEMENTS.—The research re-
quired by paragraph (1) shall include— 
(A) research concerning causes, symptoms, 
and treatments for menopause, perimenopause, 
and other related mid-life women’s health 
issues; and 
(B) a multidisciplinary study of the effects 
of hormonal treatment for menopausal symp-
toms. 
SEC. 4. NO ADDITIONAL FUNDS AUTHORIZED TO BE APPRO-
PRIATED. 
No additional funds are authorized to be appro-
priated to carry out this section, and this section shall be 
carried out using amounts otherwise available for such 
purpose. 
Æ 
VerDate Sep 11 2014 
23:38 Dec 29, 2023
Jkt 049200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\H6749.IH
H6749